Korean Journal of Nephrology 1998;17(2):258-265.

Erythropoietin 투여 후 나타난 투석막 재사용 투석효율 및 임상지표의 변하에 관한 연구

안병진 , 정안철 , 윤광식 , 문도호 , 신진 , 이성은 , 최장균 , 이승복 , 도승경 , 정예경 , 강효종 , 전용덕

Abstract

The use of erythropoietin for correction of anemia in maintenance hemodialysis patients affects dialyzer reuse, dialysis efficacy and other clinical pararneters. This study showed the change of Kt/fVurea, nPCR, pre-dialysis BUN, body weight, ultrafiltration vol- ume, pre-dialysis blood pressure, heparin dosage, the number of dialyzer reuse caused by the admini- stration of erythropoietin in reuse(n=ll) and first use(n=9) patients who were started erythropoietin since January, 1995. 1) In 20 all patients, hematocrit increased signifi- cantly after EPO treatment 20.7±0.8%, 27.8±0.7%, ultrafiltration volume increased from 2.0±0.3L to 2.5± 0.2L(P<0.05). However no significant changes were noted in Kt/Vurea, nPCR and other parameters 2) In patients of dialysis reuse, the number of reuse was not affected by EPO treatment(8.4±1.7, 9.6±1.5, P=0.67). No significant differences were observed in all parameters except hematocrit in case of first use and reuse. 3) Entire patients were reclassified into low base- line protein intake group(nPCR<1.0g/kg/day) and high baseline protein intake group(nPcR>1.0/kg/ day) and then pretreatment versus posttreatment nPCR, pre-dialysis BUN and ultrafiltration volume were compared. In low baseline protein intake group, significant increases of ultrafiltration volume, nPCR were observed. However, pre-dialysis BUN were not changed significantly. In high protein intake group, nPCR, pre-dialysis BUN, ultrafiltration volume were changed without significance. In conclusion, EPO treatment did not affect Kt/ Vurea, dialyzer reuse, nPCR, predialysis blood pres- sure, heparin dosage. But ultrafiltration volume increased significantly after EPO treatment. Maybe increased appetite in low baseline protein intake group caused the increased posttreatment ultrafil- tration volume.